AI assistant
Kitron — Earnings Release 2021
Jul 12, 2021
3643_rns_2021-07-12_59be5b27-7918-4432-891b-aca0a12c7ace.pdf
Earnings Release
Open in viewerOpens in your device viewer
Peter Nilsson, CEO Cathrin Nylander, CFO
Q2 results 2021
Kitron Group | 2021-07-12
Solid quarter and record order backlog
| NOK Million | Q2 2021 vs Q2 2020 | ||
|---|---|---|---|
| Revenue | | -4.5 % | |
| 993.8 | |||
| EBIT | | -16.9 % | |
| 73.1 | |||
| Order Backlog | | 9.1 % | |
| 2 293.5 | |||
| Operating cash flow 109.3 |
| 1875.2 % | |
| Net working capital | | -2.4 % | |
| 1 033.7 |
| NOK Million | 2021 vs 2020 | |
|---|---|---|
| Revenue 1 931.4 |
| 0.7 % |
| EBIT 138.5 |
| -5.4 % |
| Order Backlog 2 293.5 |
| 9.1 % |
| Operating cash flow 187.6 |
| 73.7 % |
| Net working capital 1 033.7 |
| -2.4 % |
Highlights and important events
- Underlying revenue growth of 5%, currency negative effect of 10%
- Strong growth in Industry and Electrification. Medical devices volumes normalized.
- Growing in line with long term targets despite challenges on supply chain and currencies
- EBIT margin 7.4% (8.4%)
- EPS NOK 0.27 (0.36), EPS YTD: 0.52 (0.59)
- Order backlog growth 9%: strong growth in Connectivity, Electrification and Industry
- Strong cash flow MNOK 109 (5)
- Dividend tranche one paid in the quarter. The second tranche of ordinary dividend for 2020 of NOK 0.35 per share, is to be paid out on or about 22 October 2021, with record date 6 October
Financial results
Electrification and Industry drives growth
| Q2 2021 vs Q2 2020 | Share of total revenue | |
|---|---|---|
| Connectivity 107.6 |
20.9 % |
10.8 % |
| Electrification 273.3 |
26.4 % |
27.5 % |
| Industry 253.9 |
30.1 % |
25.5 % |
| Medical Devices 159.6 |
-45.4 % |
16.1 % |
| Defence & Aerospace 199.5 |
-19.5 % |
20.1 % |
| Q2 2021 vs Q2 2020 | Share of total revenue | |
|---|---|---|
| Norway 287.3 |
22.2 % |
28.2 % |
| Sweden 198.8 |
9.6 % |
19.5 % |
| CEE 343.0 |
3.2 % |
33.6 % |
| Others 190.3 |
-46.9 % |
18.7 % |
Before group entities and eliminations
Currency development and selling currencies
- Currency development negatively affects growth
- Re-calculating the selling currencies shows a growth of about 5% i.e. a total ~10% currency effect.
| Selling currencies | ||||||
|---|---|---|---|---|---|---|
| EUR | USD | CNY | SEK | NOK | Mix | |
| Share of total | 27 % | 32 % | 5 % | 17 % | 19 % | |
| Currency rate change vs Q2 LY | -8 % | -17 | - 8 |
-4 % | ~10% | |
EBIT at strategic growth path
- EBIT development in line with strategic trajectory and outlook
- Economies of scale and exceptional utilization of overhead Q2/Q3 2020
- Material supply demanding 2021
Q2 EBIT by country: Strong development
- Norway and Sweden at solid margin levels and with improved profits
- CEE (Lithuania and Poland) ended at good profits and profitability levels.
- o Revenue and margins affected by volume pushouts
- Others (China and US) in total below strategic levels.
- o China at solid margin levels and US affected by lower activity but improving
| Norway | Sweden | CEE | Others |
|---|---|---|---|
| 7.4 % | 7.4 % | 7.9 % | 5.7 % |
| 6.9 % | 6.8 % | 7.2 % | 13.9 % |
Balance sheet: Capital stabilized
- Working capital ratios
- o NOWC* 25.8% (24.5%)
- o Cash conversion cycle* 96 (93)
- o ROOC* 19.1% (22.1%)
- Cash flow
- o Q2 Cash flow from operations MNOK 109 (5)
- Financial gearing
- o NIBD/EBITDA 1.7 (2.3)
- exclusive IFRS16 NIBD/EBITDA 1.5
Net working capital
Market development
Strong order backlog
▪ Growth 9% - supports the demand outlook
| Q2 2021 vs Q2 2020 | Share of total revenue | |
|---|---|---|
| Connectivity 241.2 |
131.3 % |
10.5 % |
| Electrification 678.0 |
48.3 % |
29.6 % |
| Industry 360.0 |
36.8 % |
15.7 % |
| Medical Devices 279.8 |
-37.0 % |
12.2 % |
| Defence & Aerospace 734.4 |
-11.9 % |
32.0 % |
Outlook
Outlook
- For 2021, Kitron expects revenue between NOK 3 900 and 4 200 million. EBIT margin is expected to be between 6.8 and 7.4 per cent.
- The outlook for 2021 implies that Kitron is back on its long-term trajectory for revenue and profitability after exceptional growth in 2020, largely driven by Corona-related demand within the Medical devices sector.
- Growth is driven by Connectivity, Electrification and Industry Sectors. Medical devices are expected to be normalised and in line with previous years. The outlook for Defense/Aerospace is slightly down.
- The board emphasizes that every assessment of future conditions necessarily involves an element of uncertainty
Key takeaways Summary Q2 2021
- Solid quarter despite unfavorable currencies and challenges in the supply chain.
- Order backlog and full-year demand outlook supports continued growth.
- 2021 Outlook reconfirmed and maintained.
Appendix: Definition of alternative performance measures
Order backlog
All firm orders and 4 months of committed customers forecast at revenue value as at balance sheet date.
Foreign exchange effects
Group consolidation restated with exchange rates as comparable period the previous year. Change in volume or balance calculated with the same exchange rates for the both periods are defined as underlying growth. Change based on the change in exchange rates are defined as foreign exchange effects. The sum of underlying growth and foreign exchange effects represent the total change between the periods.
EBITDA Operating profit (EBIT) + Depreciation and Impairments
EBIT Operating profit
EBIT margin (%) Operating profit (EBIT) / Revenue
Net working capital Inventory + Accounts Receivable – Accounts Payable
Operating capital Other intangible assets + Tangible fixed assets + Net working capital
Return on operating capital (ROOC) % Annualised Operating profit (EBIT) / Operating Capital
Return on operating capital (ROOC) R3 % (Last 3 months Operating profit (EBIT))*4 /(Last 3 months Operating Capital /3)
Return on capital employed (ROCE) EBIT/(Total assets - short term debt)
Return on equity Net Income/Equity
Direct Cost
Cost of material + Direct wages (subset of personnel expenses only to include personnel directly involved in production)
Days of Inventory Outstanding 360/ (Annualised Direct Costs/Inventory)
Days of Inventory Outstanding R3 360/ ((Last 3 months Direct Costs *4) /(Last 3 months Inventory/3))
Days of Receivables Outstanding 360/ (Annualised Revenue/Trade Receivables)
Days of Receivables Outstanding R3 360/ ((Last 3 months Revenue*4)/(Last 3 months Trade Receivables/3))
Days of Payables outstanding 360/ ((Annualised Cost of Material + Annualised other operational expenses) /Trade Payables)
Days of Payables Outstanding (R3) 360/ (((Last 3 months (Cost of Material + other operational expenses)*4) /(Last 3 months Trade Payables)/3))
Cash conversion cycle (CCC) Days of inventory outstanding + Days of receivables outstanding – Days of payables outstanding
Cash conversion cycle (CCC) R3
Days of inventory outstanding (R3) + Days of receivables outstanding (R3) – Days of payables outstanding (R3)
Net Interest-bearing debt
- Cash and cash equivalents + Loans (Non- current liabilities) + Loans (Current liabilities)
Interest-bearing debt Loans (Non- current liabilities) + Loans (Current liabilities)
Net gearing Net Interest-bearing debt / Equity
Free Cash flow Net Cash Flow from operating activities – Cash flows from acquisition of tangible fixed assets – Cash flows from acquisition of other intangible assets
Equity ratio Total Equity / Total Assets
EPS Earnings Per Share